Clinical trial

--SuPERIOR Trial--

NCT06191250

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2024-09-28

PhasePHASE2

Study timeline

Study start (actual)2024-09-28Date precision: day

Registry last updated2026-06-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small Cell Lung Cancer (NSCLC)unresolved

Clinical Staging T2b-3 N0-1 M0unresolved

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

Non-ablative oligofractionated radiation (NORT)RADIATION

Sponsors & collaborators

University Health Network, Torontolead sponsor

Ontario Institute for Cancer Researchcollaborator

Mapped research locations

TorontoOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06191250 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.